PAR-1 Receptor

A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2.

Also Known As:

Networked: 261 relevant articles (9 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Covic, Lidija: 8 articles (12/2020 - 03/2006)
2.	Griffin, John H: 8 articles (12/2018 - 11/2006)
3.	Kuliopulos, Athan: 7 articles (12/2020 - 03/2006)
4.	Bar-Shavit, Rachel: 6 articles (05/2012 - 01/2005)
5.	Chapman, Joab: 5 articles (06/2022 - 01/2008)
6.	Maggio, Nicola: 5 articles (06/2022 - 01/2008)
7.	Ruf, Wolfram: 5 articles (12/2020 - 07/2004)
8.	Bonaca, Marc P: 5 articles (04/2019 - 09/2009)
9.	Morrow, David A: 5 articles (04/2019 - 09/2009)
10.	Scirica, Benjamin M: 5 articles (04/2019 - 09/2009)

Related Diseases

1.	Acute Coronary Syndrome 10/13/2016 - "Protease-Activated Receptor 1 (PAR-1) Antagonists as Potential Treatment for Acute Coronary Syndrome." 07/10/2014 - "TRACER randomized 12 944 patients with non-ST-segment elevation acute coronary syndromes to placebo or to protease-activated receptor 1 antagonist vorapaxar with a median follow-up of 502 days (interquartile range, 349 to 667). " 11/01/2010 - "Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD). " 11/01/2010 - "Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease." 12/01/2020 - "PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study."
2.	Coronary Artery Disease (Coronary Atherosclerosis) 09/01/2000 - "1. The thrombin receptor (the protease-activated receptor-1; PAR-1) is located on vascular cells as well as platelets and may play important roles in atherosclerotic disorders, such as coronary artery diseases (CAD). " 11/01/2010 - "Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD). " 11/01/2010 - "Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease." 12/01/2020 - "PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study."
3.	Sepsis (Septicemia) 11/01/2023 - "Protease-activated receptor 1 (PAR1) is an important target for modulating vascular endothelial permeability; however, little research has been undertaken in sepsis, and its putative molecular mechanism remains unknown. " 12/01/2007 - "Protease-activated receptor 1 (PAR1), an important regulator of endothelial barrier function and blood coagulation, has been proposed to be involved in the lethal sequelae of sepsis, but it is unknown whether activation of PAR1 is beneficial or harmful. " 12/01/2007 - "'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage." 01/01/2018 - "The role of protease-activated receptor 1 (PAR1) in the pathogenesis of pneumonia and sepsis is ambiguous given the existing literature. " 02/26/2013 - "Protease-activated receptor-1: key player in the sepsis coagulation-inflammation crosstalk."
4.	Myocardial Infarction 01/01/2023 - "Protease-activated receptor 1 (PAR1) is crucial in individuals with acute myocardial infarction (AMI). " 09/01/2016 - "Protease activated receptor 1 (PAR1) has been considered as a promising antiplatelet target to prevent thrombotic cardiovascular events in patients with prior myocardial infarction or peripheral arterial diseases. " 11/01/2015 - "Protease activated receptor 1 (PAR1) has been considered as a promising antiplatelet target to prevent thrombotic cardiovascular events in patients with prior myocardial infarction or peripheral arterial diseases. " 01/01/2016 - "Our dual aims were as follows: (1) to classify new or recurrent myocardial infarctions (MI) in patients with stable atherosclerosis using the Universal Definition of MI classification system; and (2) to characterize the effects of vorapaxar, a first-in-class platelet protease-activated receptor -1 antagonist, on new or recurrent MI. " 11/17/2015 - "Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for thrombin on human platelets, and reduces recurrent thrombotic events in stable patients with a previous myocardial infarction (MI). "
5.	Ischemic Stroke 12/01/2018 - "This 3K3A-APC mutant exerts multiple potent neuroprotective activities, which require the G-protein-coupled receptor, protease activated receptor 1. Potent neuroprotection in murine ischemic stroke models is linked to 3K3A-APC-induced signaling that arises due to APC's cleavage in protease activated receptor 1 at a noncanonical Arg46 site. " 01/01/2017 - "Brain thrombin activity is increased following acute ischemic stroke and may play a pathogenic role through the protease-activated receptor 1 (PAR1). " 04/24/2013 - "Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1." 01/01/2014 - "The cytoprotective effects are protease activated receptor 1 (PAR-1) and endothelial protein C receptor (EPCR) dependent and likely underlie protective effects of APC in animal models of sepsis, myocardial infarction and ischemic stroke. "

Related Drugs and Biologics

1.	Endothelial Protein C Receptor
2.	PAR-2 Receptor
3.	sarsasapogenin
4.	Thrombin Receptors (Thrombin Receptor)
5.	Thrombin
6.	vorapaxar
7.	2-f)quinazoline-1,3-diamine N3- cyclopropyl- 7- ((4- (1- methylethyl)phenyl)methyl)- 7H- pyrrolo(3
8.	Rivaroxaban
9.	Prothrombin (Factor II)
10.	Arrestin

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Secondary Prevention
4.	Quantum Dots (Quantum Dot)
5.	Thrombolytic Therapy